ArticleArchives of toxicology2026
Extrapolation of in vitro effect concentrations to in vivo bioavailable concentrations using PBK modelling in humans for two classes of persistent and mobile compounds: triazoles and triazines.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complex Distribution Phenomena and Plastic Binding of Test Chemicals in Cell Culture Experiments: Exemplification by Tebufenpyrad.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bottom-up in vitro ADME parameterized PBK models play a vital role in Next Generation Risk Assessment (NGRA), which evaluates the toxicological hazards of compounds through New Approach Methods (NAMs). The ZeroPM project, funded by the EU under Horizon 2020, develops strategies to prioritize persistent (P) and mobile (M) compounds for regulatory measures based on exposure levels and toxicological properties. This study developed a quantitative in vitro to in vivo extrapolation (QIVIVE) approach for two classes of PM compounds - 9 triazines and 16 triazoles. The virtual in vitro distribution model (VIVD) derived free medium benchmark concentration values (EC20 and IR1.5 (mol/L)) from a previously published NAMs testing battery. The VIVD model accounted for partitioning and ionization of PM compounds, while a bottom-up PBK model using in vitro ADME data accurately predicted rat plasma concentrations for tebuconazole and cyromazine. The same assumptions were translated to a human oral-route PBK model. Most triazines/triazoles had in vitro ADME data, where the data gaps were filled using read-across approach. The human PBK model employed forward dosimetry to estimate plasma concentrations from preclinical lowest observed adverse effect levels (LOAELs) or hypothetical exposure data, using surface- and groundwater concentrations as worst-case scenarios. Comparison to QIVIVE data indicates that NAMs-derived values are protective and can serve as basis for human risk assessment or risk-based prioritization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.